PIPC, alongside the United Spinal Association, requested changes to the VA National Formulary Act to ensure changes to the formulary development process are centered on patients and people with disabilities.
|
PIPC has submitted another correspondence to the Minnesota PDAB urging the board to pause its work and work with patients and people with disabilities to make sure they are put first when it comes to decisions that impact treatment affordability.
Debate over drug pricing and health care affordability in the U.S. has put a renewed spotlight on costs in other countries compared to the U.S., and on the tools used in other countries to control costs.
PIPC submitted a letter to Michigan lawmakers in response to a provision within SB 857 to fund policies that would import discriminatory QALYs from other countries by way of "Most Favored Nation" agreements.
The Louisiana legislature was contacted by PIPC and others requesting the state avoid policies such as proposed in SB 401 that would devalue disabled lives by referencing measures such as the Quality-Adjusted Life Year (QALY) that have detrimental implications for access to needed care and treatment. As drafted, SB 401 would reference drug prices in other countries, thereby importing their use of QALYs and similar measures to value treatments, an algorithm that devalues the patients and people with disabilities that stand to most benefit from innovation. PIPC encourages the Louisiana legislature to pause its consideration of this legislation and to consider alternative strategies that are focused on improving affordable access to care for people with disabilities and serious chronic conditions. Read PIPC's and COGI's comments below. 
PIPC submitted a letter to a pair of State Senators in Virginia voicing continued concern about SB 271 due to the bill’s discriminatory implications for people with disabilities and patients with chronic conditions.
Rare Disease Toolkit: Resources for the Rare Disease Community Fighting to Value Our Health2/27/2026
PIPC is pleased to provide resources to the rare disease community highlighting how QALYs as used in health care value assessments devalue the lives of people with rare diseases and conditions.
PIPC and more than 100 organizations representing patients, people with disabilities, and older adults submitted a letter to the Center for Medicare and Medicaid Innovation (CMMI) regarding the use of the GLOBE and GUARD models proposed as payment models for CMMI that would import QALYs and similar measures as used in other countries.
PIPC shared the concerns of patients and people with disabilities related to efforts in Virginia to establish a Prescription Drug Affordability Board (PDAB) with the Virginia Subcommittee on Health and Human Resources in a letter to the sponsors of bills that would devalue patients, people with disabilities, and older adults.
PIPC recently submitted a letter to the sponsors of legislation (HB 483/SB 271) in Virginia that would allow the use of discriminatory "value" assessment metrics like the quality-adjusted-life-years (QALY) in health care coverage decisions.
|
|||||
